The SDRNT1BIO was established to support collaborative research use. We aim to maintain the balance of promoting the use of this unique resource for novel research that will augment existing data and knowledge, with ensuring required data governance and security. We have collaborated with a wide range of international researchers for SDRNT1BIO research: Broad Institute; Massachusetts, USAFolkhälsan/FinnDiane Study Group; Helsinki, FinlandGeneration Scotland; University of Edinburgh, ScotlandGenos; Zagreb, CroatiaHarvard University; Boston, USAHospital for Sick Children; Toronto, CanadaJoslin Diabetes Center; Massachusetts, USAKing’s College LondonSteno Diabetes Center; Copenhagen, DenmarkUniversity of California, USAUniversity of CambridgeUniversity of DundeeUniversity of ExeterUniversity of GlasgowUniversity of Michigan, USAUniversity of Pittsburgh, USAUniversity of Toronto, CanadaUniversity of Virginia, USAUniversity of Washington, USAUniversity of Wisconsin, USACollaborating laboratories that have carried out biomarker measurements on SDRNT1BIO samples include:Myriad RBM; Texas, USANational Institute of Bioprocessing Research and Training (NIBRT); Dublin, IrelandImmunoassay Biomarker Core Laboratory; Dundee, UKWellcome Trust Clinical Research Facility; Edinburgh, UKExeter Clinical Laboratory, Royal Devon and Exeter Hospital; Exeter, UKWell Child Laboratory, King’s College; London, UK Interested collaborators should contact the Study PI in the first instance, email helen.colhoun@ed.ac.ukApplications for collaboration will be assessed on an individual basis, and there are a number of specific criteria for approval, including a scientifically justified and feasible research question from an authentic researcher attached to a research institution. Please get in touch for more information. SDRNT1BIO collaborators from institutions and laboratories around the world, including the USA, Canada, Europe and the United Kingdom. This article was published on 2025-10-28